<DOC>
	<DOCNO>NCT00006094</DOCNO>
	<brief_summary>Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining chemotherapy , radiation therapy , surgery may effective treatment cancer rectum . Phase II trial study effectiveness combine oxaliplatin , fluorouracil , external-beam radiation therapy follow surgery treating patient locally advanced cancer rectum</brief_summary>
	<brief_title>Oxaliplatin , Fluorouracil , External-Beam Radiation Therapy Followed Surgery Treating Patients With Locally Advanced Cancer Rectum</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose oxaliplatin combine fluorouracil external beam radiotherapy patient locally advance adenocarcinoma rectum . ( Phase I close accrual effective 03/27/2003 ) . II . Determine pathological response rate patient treat preoperative regimen surgical resection . III.Determine late toxicity preoperative regimen patient . IV . Determine , preliminary manner , progression-free survival , local control , overall survival patient treat regimen . OUTLINE : This dose-escalation , multicenter study oxaliplatin . Patients receive oxaliplatin IV 1 hour day 1 , fluorouracil IV continuously day 1-7 , radiotherapy day 1-5 . Treatment repeat weekly maximum 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos oxaliplatin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional patient treat dose level phase II portion study . ( Phase I close accrual effective 03/27/2003 ) . Patients may undergo radical resection rectal tumor within 4-6 week completion chemoradiotherapy . Patients follow every 3 month 2 year every 6 month 3 year . PROJECTED ACCRUAL : A total 9-24 patient accrued phase I study ( phase I close accrual effective 03/27/2003 ) total 19 patient accrue phase II study within 12-18 month .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically proven previously untreated adenocarcinoma rectum thatbegins within 12 cm anal verge sigmoidoscopy and/or colonoscopy Locally advance disease define follow : Fixed immovable tumor physical exam T4 disease invasion adjacent structure ( e.g. , pelvic sidewall , sacral pelvis , bladder , prostate ) CT scan , rectal ultrasound , MRI T3 disease invasion wall muscularis propria transrectal ultrasound , CT scan , MRI No distant metastatic disease Performance status ECOG 02 Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Bilirubin great upper limit normal ( ULN ) SGOT/SGPT great 2.5 time ULN Creatinine great 1.5 mg/dL Creatinine clearance least 60 mL/min No active second malignancy except nonmelanomatous skin cancer carcinoma situ cervix Patients consider active second malignancy complete therapy le 30 % risk relapse No prior concurrent evidence neuropathy No history allergy platinum compound antiemetic Not pregnant nursing Fertile patient must use effective contraception No prior fluorouracil platinumbased therapy malignancy No concurrent chemotherapy Hormonal therapy allow nondisease related condition ( e.g. , insulin diabetes ) OR intermittently antiemetic ( e.g. , dexamethasone ) No prior pelvic irradiation No concurrent antiretroviral therapy ( HAART ) HIV positive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>